FDA
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
Maybe timing is everything. On Aug. 28, 2017, Gilead acquired Kite for about $11.9B.
Officially, there have been four new chemical entities have been approved since our last issue.
PRESS RELEASES